Related Experiment Video

Updated: Aug 8, 2026

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors

Published on: July 17, 2020

Osteopontin is a downstream effector of the PI3-kinase pathway in melanomas that is inversely correlated with

Leisl Packer1, Sandra Pavey, Andrew Parker

  • 1Human Genetics Laboratory, Queensland Institute of Medical Research, Herston 4006, QLD, Australia. Leisl.Packer@qimr.edu.au

Carcinogenesis
|March 31, 2006
PubMed

Insights

Loss of the tumor suppressor PTEN in melanoma elevates Osteopontin (OPN) expression, a key driver of tumor progression. This study identifies OPN as a downstream target of phosphatidylinositol 3-kinase (PI3K) signaling in melanoma.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • The tumor suppressor PTEN regulates the phosphatidylinositol 3-kinase (PI3K) pathway, crucial in tumorigenesis.
  • PTEN mutations are observed in melanoma, but their downstream effects remain unclear.
  • Understanding PTEN's role is vital for developing targeted melanoma therapies.

Purpose of the Study:

  • To identify novel downstream effectors of PI3K signaling in melanoma.
  • To elucidate the mechanistic consequences of PTEN aberrations in melanoma.
  • To investigate the role of Osteopontin (OPN) in PTEN-mutated melanoma.

Main Methods:

  • Genomic analysis (microarray) of 53 melanoma cell lines with varying PTEN status.
  • Quantitative reverse transcription PCR (qRT-PCR) for gene expression validation.
  • Immunohistochemistry on melanoma tissue microarrays.
  • Pharmacological inhibition of PI3K using LY294002.

Main Results:

  • Microarray analysis revealed 610 differentially expressed genes between PTEN wild-type and aberrant melanoma cell lines.
  • Osteopontin (OPN) mRNA and protein levels were significantly higher in PTEN-mutant melanoma.
  • A strong inverse correlation between OPN and PTEN expression was confirmed in melanoma tissues.
  • PI3K inhibition reduced OPN expression, indicating OPN acts downstream of PI3K.

Conclusions:

  • Osteopontin (OPN) is identified as a downstream target of PI3K signaling in melanoma.
  • Loss of PTEN function in melanoma leads to increased OPN expression.
  • These findings provide insights into melanoma development driven by PTEN loss and PI3K pathway activation.

More Related Videos

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma08:18

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma

Published on: September 8, 2021

Development of Compendium for Esophageal Squamous Cell Carcinoma03:36

Development of Compendium for Esophageal Squamous Cell Carcinoma

Published on: April 12, 2024

Related Concept Videos

Phosphoinositides and PIPs01:42

Phosphoinositides and PIPs

Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...